At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Axalimogene filolisbacdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal
In Brief
A Phase 2 clinical trial evaluating Axalimogene filolisbac for Anal Cancer and Rectal Cancer. Completed, enrolled 36 participants across 10 sites.
Detailed Summary
This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 participants, respectively with persistent/recurrent, loco-regional or metastatic squamous cell carcinoma (SCCA) of the anorectal canal that have received at least 1 regimen for the treatment of advanced disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnal Cancer, Rectal Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartJun 2016
Primary CompletionJan 2019
TodayJul 2026
First PostedMar 26, 2015
Enrollment StartJun 2, 2016
Primary CompletionJan 3, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.3 years ago
Interventions
Axalimogene filolisbacdrug